|Bid||10.30 x 0|
|Ask||10.40 x 0|
|Day's range||10.20 - 10.20|
|52-week range||9.95 - 17.90|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||25 Apr 2023 - 01 May 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
BURLINGAME, Calif., March 13, 2023--Innoviva, Inc. (Nasdaq: INVA) ("Innoviva"), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that the U.S. Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee will convene April 17, 2023 to review data supporting the new drug application (NDA) for sulbactam-durlobactam (SUL-DUR).
BURLINGAME, Calif., February 28, 2023--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or "the Company"), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the fourth quarter ended December 31, 2022.
Investors can approximate the average market return by buying an index fund. Active investors aim to buy stocks that...